TNFRSF17 and Miyoshi myopathy: It is also a phase 3, randomized, open-label, international study aimed to involve 750 patients from about 52 clinical sites (multicenter) to compare the efficacy and safety of DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone) followed by a single infusion of cilta-cel (target dose of 0.75×106 CAR-positive viable T-cells/kg) versus DVRd followed by autologous stem cell transplant (ASCT) in patients with newly diagnosed MM who are not exposed to prior BCMA targeted therapy (73).